Alzheimer's Research: Billions Spent, Scientific Scandal, and the Search for a Different Way Forward
For decades, Alzheimer's disease has been one of the great unresolved tragedies of modern medicine. Enormous sums have been invested in research, thousands of scientific papers have been published, and pharmaceutical companies have pursued the prospect of a treatment for a disease that devastates not only patients but entire families. Yet the results remain disappointingly modest. There is still no cure, and even the newest generation of drugs offers, at best, a slowing of deterioration for some patients rather than the restoration of lost cognitive function.
The November 14, 2026 article by A Midwestern Doctor, entitled "The Forgotten Causes of Alzheimer's and the Cures They've Buried," raises a fundamental question: has Alzheimer's research become trapped within a dominant scientific paradigm that has absorbed billions of dollars while discouraging potentially fruitful alternatives? The article argues that the medical establishment's overwhelming concentration on amyloid proteins has diverted attention from vascular dysfunction, chronic inflammation, metabolic abnormalities and other possible causes of cognitive decline.
Some of its claims about overlooked treatments go considerably further than the clinical evidence currently warrants. Nevertheless, the central challenge deserves serious consideration. A scientific establishment should be judged not by the prestige of its researchers, the size of its grants or the commercial value of its discoveries, but by whether its theories survive critical examination and produce meaningful improvements for patients.
The history of Alzheimer's research provides an uncomfortable example of what happens when these standards become confused.
The dominant explanation of Alzheimer's disease has long centred on the accumulation of amyloid-beta proteins in the brain. These proteins can aggregate into plaques, one of the characteristic pathological features of the disease. Beginning in the 1980s and 1990s, biochemical and genetic discoveries encouraged researchers to believe that amyloid accumulation was a principal driver of the neurodegenerative process. If amyloid could be prevented from accumulating, or removed once present, perhaps the disease could be stopped.
This was not an irrational hypothesis. Rare inherited forms of Alzheimer's disease are associated with mutations affecting amyloid production, providing substantial evidence that amyloid biology can play a causal role. The difficulty was that repeated attempts to translate this understanding into effective treatments produced disappointing results.
The situation became particularly controversial following the publication of a highly influential paper in Nature in 2006. The study, led by Sylvain Lesné and colleagues, claimed that a particular soluble amyloid assembly, known as Aβ*56, could impair memory. It offered an apparently compelling explanation for how cognitive deterioration might begin before the extensive formation of visible plaques.
The paper attracted thousands of citations and became an influential contribution to the literature. Yet serious questions eventually emerged about the integrity of its experimental images. Investigations highlighted evidence of image manipulation, and in June 2024 Nature formally retracted the article. The retraction notice identified signs of splicing, duplication and the use of an eraser tool, while stating that the underlying data could not be verified. Lesné disagreed with the retraction, and the notice did not establish the personal responsibility of every author.
This was a major scientific scandal, not a minor disagreement over statistical interpretation. Research published in one of the world's most prestigious scientific journals had remained influential for nearly two decades before being withdrawn over fundamental concerns about the reliability of its evidence.
However, it would be a mistake to conclude that the entire amyloid hypothesis was thereby exposed as fraudulent. The hypothesis existed before the 2006 paper and rests on multiple independent lines of investigation. Indeed, the US National Institute on Aging has emphasised that the particular Aβ*56 finding was never the sole foundation of amyloid research and had proved difficult to reproduce.
The deeper issue is institutional. How could such questionable work acquire substantial influence, and why did the scientific system take so long to correct the record? What happens when researchers have invested their careers in a particular explanatory framework, universities have built research programmes around it, and funding agencies have committed vast resources to its development?
Science is supposed to be self-correcting. But self-correction can be painfully slow when professional reputations, financial interests and institutional prestige become entangled with a dominant theory.
The most important recent development is not simply the exposure of unreliable research, but the continuing dispute over whether amyloid-targeting drugs deliver benefits sufficient to justify their risks and costs.
In April 2026, the independent Cochrane Collaboration published a systematic review of 17 clinical trials involving 20,342 participants. Its conclusion was striking: anti-amyloid antibody treatments produced effects on cognitive decline that were absent or too small to be considered clinically meaningful, while increasing the risks of brain swelling and bleeding.
This does not mean that the drugs have no biological effect. Treatments such as lecanemab and donanemab can reduce amyloid accumulation, and individual clinical trials have reported statistically significant slowing of cognitive deterioration. Supporters argue that even modest delays could matter to patients and families, particularly if treatment begins early. Critics counter that a measurable change on a clinical rating scale is not necessarily a perceptible improvement in everyday life. Some experts have also questioned whether the Cochrane review's pooling of different antibodies obscures differences between individual treatments.
There is, however, a fundamental problem when a drug successfully removes its intended biological target but produces only limited clinical benefits. The result invites reconsideration of whether that target is sufficiently central to the disease process, whether intervention occurs too late, or whether other pathological mechanisms continue independently of amyloid accumulation.
For patients and families, this distinction is crucial. They are not primarily interested in improved laboratory measurements or impressive brain scans. They want to know whether a person will remember loved ones, retain independence, communicate meaningfully and enjoy additional years of reasonable cognitive function.
The medical establishment must be willing to distinguish between a technically successful intervention and a genuinely worthwhile treatment.
One of the strongest aspects of the Midwestern Doctor article is its insistence that Alzheimer's disease should not be understood exclusively through a single molecular pathway.
The brain is extraordinarily dependent upon an adequate blood supply. Its neurons require continuous oxygen and energy, while the vascular system helps regulate inflammation and the removal of metabolic waste. Damage to small blood vessels, impaired circulation and disruption of the blood-brain barrier may therefore contribute to cognitive deterioration.
Vascular dementia is already a recognised medical condition, but vascular abnormalities can also coexist with Alzheimer's pathology. This raises the possibility that some patients experience several interacting disease processes rather than a single, neatly isolated disorder.
The article discusses impaired cerebral circulation, abnormal aggregation of blood cells, and disturbances in venous and lymphatic drainage. These are legitimate subjects for investigation, although some of the specific mechanisms it advances, including its account of blood sludging, require much stronger clinical validation before they can be regarded as established explanations of Alzheimer's disease.
Inflammation offers another important research direction. The brain's immune cells, particularly microglia, respond to injury, infection and abnormal protein accumulation. These responses may initially be protective but can potentially become damaging when chronically activated. Understanding the circumstances under which inflammation protects neurons or contributes to their destruction could reveal therapeutic possibilities beyond simply removing amyloid.
Metabolic dysfunction is equally significant. Insulin resistance, diabetes, mitochondrial abnormalities and impaired cellular energy production have all attracted attention in dementia research. The expression type 3 diabetes has sometimes been used to describe proposed connections between insulin signalling and Alzheimer's disease, although it is not an established clinical diagnosis.
The central lesson is that the brain cannot be separated from the health of the rest of the body. Cardiovascular disease, metabolic disturbances, chronic inflammation and neurodegeneration may be interconnected, with their relative importance varying between patients.
This suggests that the search for a universal Alzheimer's drug may be too narrow. A more productive approach might identify different biological pathways contributing to cognitive decline and investigate treatments directed at those pathways, either individually or in combination.
The Midwestern Doctor article goes beyond conventional vascular and metabolic research to advocate reconsideration of treatments that have received relatively little attention.
It discusses the work of neurologist Dale Bredesen, whose approach seeks to identify and address multiple potentially contributing factors in patients experiencing cognitive decline. These may include metabolic abnormalities, nutritional deficiencies, inflammation, sleep disturbances and other medical problems.
The attraction of such an approach is obvious. Rather than assuming that every patient has an identical biological problem requiring an identical pharmaceutical solution, it attempts to understand the individual circumstances of the patient.
However, this is also where scientific caution becomes essential. Multicomponent treatment programmes are difficult to evaluate because improvement cannot necessarily be attributed to any particular intervention. Encouraging preliminary findings do not establish that a programme can reliably reverse Alzheimer's disease. Larger, independently replicated and rigorously controlled trials are needed.
The article also promotes dimethyl sulfoxide, or DMSO, drawing upon experimental research, older clinical reports and patient testimonials. Some laboratory and animal studies have investigated its effects on inflammation, circulation and neurological injury. But these findings do not establish that DMSO is an effective or safe treatment for human Alzheimer's disease. Anecdotes of dramatic improvement, however moving, cannot substitute for controlled clinical evidence, and oral or intravenous self-treatment would be unjustified.
The appropriate response is neither automatic dismissal nor uncritical enthusiasm. Where plausible biological mechanisms and credible preliminary evidence exist, researchers should be free to investigate them. But alternative treatments must meet the same standards of evidence demanded of expensive pharmaceutical products. Otherwise, criticism of one scientific orthodoxy merely creates another.
The broader controversy concerns the institutional organisation of medical research.
Modern biomedical science is an enormous enterprise involving universities, pharmaceutical companies, government agencies, professional associations and academic journals. These institutions perform essential work, but they also create incentives that can shape the questions researchers ask.
A young scientist pursuing an unconventional hypothesis may find it difficult to secure grants, publish in prestigious journals or establish a career. Research that extends an established programme can appear less risky to funding committees, even when that programme has produced limited clinical success.
Once a research paradigm becomes dominant, an institutional feedback mechanism can emerge. Researchers trained within the paradigm assess grant applications, review papers, supervise students and influence research priorities. The system can reward conformity without requiring an explicit conspiracy.
Pharmaceutical economics adds another dimension. Developing a new drug is enormously expensive, and companies understandably seek products capable of generating sufficient revenue to recover their investments. Patentable molecular treatments may therefore attract commercial resources unavailable to inexpensive preventive interventions or therapies with limited commercial exclusivity.
Institutional incentives may produce systematic neglect even without deliberate suppression. A promising line of inquiry can remain underdeveloped because it lacks commercial backing, conflicts with prevailing assumptions or falls outside established funding priorities.
It is possible to criticise the structure of biomedical research without claiming that every disappointing result is evidence of corruption or that every neglected therapy is a hidden cure.
Indeed, the Alzheimer's scandal demonstrates why scepticism must operate in both directions. The manipulation of experimental images undermines confidence in the research concerned, while exaggerated claims for alternative treatments can exploit the same public frustration that scientific misconduct has helped create.
The solution is not to replace one privileged authority with another, but to strengthen independent scrutiny, reproducibility and intellectual competition.
While researchers continue searching for more effective treatments, one of the most promising areas of dementia policy is prevention.
The 2024 Lancet Commission on dementia identified 14 potentially modifiable risk factors, including hypertension, diabetes, physical inactivity, smoking, hearing impairment, untreated vision loss, high cholesterol, social isolation and air pollution. Its modelling suggested that addressing these factors might prevent or delay a substantial proportion of dementia cases, potentially approaching half at the population level. That is a population estimate, not a guarantee that individual cases can be prevented.
These findings are important because many of the relevant interventions are already familiar: managing cardiovascular risk, encouraging physical activity, treating hearing and vision problems, reducing smoking and supporting social engagement. Such measures are not miraculous cures, and they cannot eliminate the influence of ageing or genetics. Nevertheless, they offer opportunities for practical action without waiting for the next pharmaceutical breakthrough.
There is also a strong economic argument for taking prevention more seriously. Delaying the onset of dementia, even without eliminating the disease, could reduce the burden on families, hospitals, residential care facilities and public budgets.
This is particularly relevant to Australia, with its ageing population and growing demands upon health and aged-care services. A research strategy overwhelmingly concerned with costly interventions after cognitive decline has begun risks overlooking the benefits of addressing modifiable risks decades earlier.
The Alzheimer's controversy illustrates a larger problem within contemporary science. A research programme can acquire enormous intellectual and financial momentum, making it increasingly difficult to distinguish continued investment from genuine progress. The temptation is always to defend past commitments rather than reconsider the assumptions upon which they were built.
Yet the history of science is filled with theories that once appeared unassailable and were subsequently revised or displaced. Scientific progress depends upon the willingness to confront inconvenient evidence, particularly when that evidence threatens established reputations and institutions.
Alzheimer's patients and their families have waited long enough for meaningful progress. They deserve neither exaggerated promises from pharmaceutical companies nor unsupported assurances from alternative practitioners. They deserve a research culture that is prepared to test competing explanations rigorously, acknowledge failure and redirect resources when the evidence demands it.
